Halozyme Therapeutics, Inc. (HALO)
USD 57.78
(-3.33%)
USD 57.78
(-3.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 281.59 Million USD | 39.31% |
| 2022 | 202.12 Million USD | -49.81% |
| 2021 | 402.71 Million USD | 211.97% |
| 2020 | 129.08 Million USD | 278.69% |
| 2019 | -72.24 Million USD | 10.07% |
| 2018 | -80.33 Million USD | -227.57% |
| 2017 | 62.97 Million USD | 161.12% |
| 2016 | -103.02 Million USD | -219.64% |
| 2015 | -32.23 Million USD | 52.86% |
| 2014 | -68.37 Million USD | 18.09% |
| 2013 | -83.47 Million USD | -55.88% |
| 2012 | -53.55 Million USD | -170.88% |
| 2011 | -19.76 Million USD | 62.87% |
| 2010 | -53.24 Million USD | 8.77% |
| 2009 | -58.36 Million USD | -19.95% |
| 2008 | -48.65 Million USD | -103.61% |
| 2007 | -23.89 Million USD | -61.99% |
| 2006 | -14.75 Million USD | -11.12% |
| 2005 | -13.27 Million USD | -46.02% |
| 2004 | -9.09 Million USD | -11394.83% |
| 2003 | -79.09 Thousand USD | -21.19% |
| 2002 | -65.26 Thousand USD | -64.59% |
| 2001 | -39.65 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 93.24 Million USD | 21.38% |
| 2024 Q1 | 76.82 Million USD | -10.03% |
| 2024 Q3 | 137.01 Million USD | 46.94% |
| 2023 Q2 | 74.75 Million USD | 88.7% |
| 2023 Q3 | 81.83 Million USD | 9.48% |
| 2023 Q4 | 85.38 Million USD | 4.34% |
| 2023 FY | 281.59 Million USD | 39.31% |
| 2023 Q1 | 39.61 Million USD | -31.35% |
| 2022 Q3 | 61.63 Million USD | 171.69% |
| 2022 Q1 | 60.1 Million USD | -9.98% |
| 2022 Q2 | 22.68 Million USD | -62.26% |
| 2022 FY | 202.12 Million USD | -49.81% |
| 2022 Q4 | 57.7 Million USD | -6.38% |
| 2021 FY | 402.71 Million USD | 211.97% |
| 2021 Q4 | 66.77 Million USD | -69.17% |
| 2021 Q3 | 216.58 Million USD | 136.82% |
| 2021 Q2 | 91.45 Million USD | 227.87% |
| 2021 Q1 | 27.89 Million USD | -61.87% |
| 2020 Q2 | 25.81 Million USD | 523.02% |
| 2020 Q1 | -6.1 Million USD | 82.26% |
| 2020 Q3 | 36.2 Million USD | 40.24% |
| 2020 FY | 129.08 Million USD | 278.69% |
| 2020 Q4 | 73.16 Million USD | 102.07% |
| 2019 Q2 | -14.62 Million USD | -914.25% |
| 2019 Q3 | -25.01 Million USD | -71.05% |
| 2019 Q4 | -34.39 Million USD | -37.51% |
| 2019 FY | -72.24 Million USD | 10.07% |
| 2019 Q1 | 1.79 Million USD | 184.48% |
| 2018 Q1 | -27.46 Million USD | -122.17% |
| 2018 FY | -80.33 Million USD | -227.57% |
| 2018 Q4 | -2.12 Million USD | 92.37% |
| 2018 Q3 | -27.85 Million USD | -21.65% |
| 2018 Q2 | -22.89 Million USD | 16.63% |
| 2017 Q4 | 123.88 Million USD | 4406.44% |
| 2017 Q3 | 2.74 Million USD | 108.94% |
| 2017 Q2 | -30.76 Million USD | 6.49% |
| 2017 Q1 | -32.89 Million USD | -20.12% |
| 2017 FY | 62.97 Million USD | 161.12% |
| 2016 Q3 | -28.94 Million USD | -7.71% |
| 2016 Q4 | -27.38 Million USD | 5.39% |
| 2016 FY | -103.02 Million USD | -219.64% |
| 2016 Q2 | -26.87 Million USD | -35.62% |
| 2016 Q1 | -19.81 Million USD | -558.92% |
| 2015 Q4 | 4.31 Million USD | 117.65% |
| 2015 Q3 | -24.46 Million USD | -910.2% |
| 2015 Q2 | 3.01 Million USD | 119.98% |
| 2015 Q1 | -15.1 Million USD | -186.46% |
| 2015 FY | -32.23 Million USD | 52.86% |
| 2014 Q2 | -16.27 Million USD | 38.7% |
| 2014 FY | -68.37 Million USD | 18.09% |
| 2014 Q1 | -26.54 Million USD | -20.75% |
| 2014 Q4 | -5.27 Million USD | 73.99% |
| 2014 Q3 | -20.28 Million USD | -24.62% |
| 2013 Q3 | -19.29 Million USD | 15.8% |
| 2013 FY | -83.47 Million USD | -55.88% |
| 2013 Q1 | -19.28 Million USD | -337.79% |
| 2013 Q4 | -21.98 Million USD | -13.96% |
| 2013 Q2 | -22.91 Million USD | -18.78% |
| 2012 Q4 | -4.4 Million USD | 77.98% |
| 2012 Q1 | -15.11 Million USD | 17.9% |
| 2012 Q3 | -20 Million USD | -42.68% |
| 2012 Q2 | -14.02 Million USD | 7.26% |
| 2012 FY | -53.55 Million USD | -170.88% |
| 2011 FY | -19.76 Million USD | 62.87% |
| 2011 Q1 | -9.63 Million USD | 42.96% |
| 2011 Q2 | 3.11 Million USD | 132.34% |
| 2011 Q3 | 5.16 Million USD | 65.75% |
| 2011 Q4 | -18.41 Million USD | -456.53% |
| 2010 Q4 | -16.89 Million USD | -36.13% |
| 2010 FY | -53.24 Million USD | 8.77% |
| 2010 Q3 | -12.4 Million USD | -2.13% |
| 2010 Q2 | -12.15 Million USD | -3.08% |
| 2010 Q1 | -11.78 Million USD | 6.93% |
| 2009 Q1 | -14.72 Million USD | 12.48% |
| 2009 FY | -58.36 Million USD | -19.95% |
| 2009 Q2 | -17.06 Million USD | -15.85% |
| 2009 Q4 | -12.66 Million USD | 8.95% |
| 2009 Q3 | -13.91 Million USD | 18.46% |
| 2008 Q3 | -10.87 Million USD | 1.18% |
| 2008 FY | -48.65 Million USD | -103.61% |
| 2008 Q4 | -16.82 Million USD | -54.76% |
| 2008 Q2 | -11 Million USD | -10.53% |
| 2008 Q1 | -9.95 Million USD | -14.3% |
| 2007 Q3 | -7.02 Million USD | -46.38% |
| 2007 Q4 | -8.7 Million USD | -23.9% |
| 2007 Q1 | -3.35 Million USD | 23.31% |
| 2007 FY | -23.89 Million USD | -61.99% |
| 2007 Q2 | -4.8 Million USD | -43.02% |
| 2006 Q1 | -3.49 Million USD | 0.66% |
| 2006 FY | -14.75 Million USD | -11.12% |
| 2006 Q3 | -3.65 Million USD | -12.94% |
| 2006 Q4 | -4.37 Million USD | -19.91% |
| 2006 Q2 | -3.23 Million USD | 7.38% |
| 2005 Q2 | -2.86 Million USD | 10.17% |
| 2005 Q4 | -3.51 Million USD | 5.05% |
| 2005 FY | -13.27 Million USD | -46.02% |
| 2005 Q3 | -3.7 Million USD | -29.01% |
| 2005 Q1 | -3.19 Million USD | -28.8% |
| 2004 Q4 | -2.47 Million USD | 23.79% |
| 2004 Q1 | -1.28 Million USD | -2282.18% |
| 2004 Q2 | -2.07 Million USD | -61.53% |
| 2004 FY | -9.09 Million USD | -11394.83% |
| 2004 Q3 | -3.25 Million USD | -56.8% |
| 2003 FY | -79.09 Thousand USD | -21.19% |
| 2003 Q1 | -9874.00 USD | 78.51% |
| 2003 Q2 | -4849.00 USD | 50.89% |
| 2003 Q4 | -53.91 Thousand USD | -469.84% |
| 2003 Q3 | -9462.00 USD | -95.13% |
| 2002 Q3 | -12.61 Thousand USD | 21.55% |
| 2002 Q1 | 9362.00 USD | 0.0% |
| 2002 Q4 | -45.94 Thousand USD | -264.32% |
| 2002 FY | -65.26 Thousand USD | -64.59% |
| 2002 Q2 | -16.07 Thousand USD | -271.69% |
| 2001 FY | -39.65 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 292.348% |
| Alkermes plc | 355.75 Million USD | 20.847% |
| Agenus Inc. | -245.76 Million USD | 214.58% |
| Aptorum Group Limited | -2.82 Million USD | 10069.175% |
| Ardelyx, Inc. | -66.06 Million USD | 526.225% |
| Dyadic International, Inc. | -6.79 Million USD | 4243.854% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 30184.829% |
| Lantern Pharma Inc. | -15.96 Million USD | 1864.204% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 1579.824% |
| Novavax, Inc. | -545.06 Million USD | 151.663% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 583.067% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 481.615% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 1618.347% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 2919.888% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 577.418% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 175.367% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 1256.952% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 854.135% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 271.105% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 483.92% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 1487.778% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 552.324% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 966.843% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 312.535% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 163.963% |
| AlloVir, Inc. | -190.41 Million USD | 247.882% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 237.179% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 1089.716% |
| Bicycle Therapeutics plc | -180.66 Million USD | 255.866% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 257.269% |
| ChromaDex Corporation | -4.93 Million USD | 5802.592% |
| Chimerix, Inc. | -82.09 Million USD | 443.01% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 731.33% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 375.883% |
| CRISPR Therapeutics AG | -153.61 Million USD | 283.317% |
| Precision BioSciences, Inc. | -61.31 Million USD | 559.228% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 274.981% |
| Fortress Biotech, Inc. | -60.63 Million USD | 564.393% |
| Fortress Biotech, Inc. | -60.63 Million USD | 564.393% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 445.175% |
| ImmuCell Corporation | -5.77 Million USD | 4976.426% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 349.284% |
| Immix Biopharma, Inc. | -15.42 Million USD | 1925.445% |
| Incyte Corporation | 597.59 Million USD | 52.879% |
| Innoviva, Inc. | 179.72 Million USD | -56.683% |
| IO Biotech, Inc. | -86.08 Million USD | 427.119% |
| Jaguar Health, Inc. | -41.3 Million USD | 781.826% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 284.058% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -439.928% |
| ContextLogic Inc. | -317 Million USD | 188.831% |
| MiMedx Group, Inc. | 67.43 Million USD | -317.554% |
| MEI Pharma, Inc. | 17.77 Million USD | -1483.946% |
| NextCure, Inc. | -62.72 Million USD | 548.949% |
| Onconetix, Inc. | -37.4 Million USD | 852.73% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 813.275% |
| Opthea Limited | -220.24 Million USD | 227.857% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 650.429% |
| Vaxcyte, Inc. | -402.26 Million USD | 170.002% |
| PDS Biotechnology Corporation | -42.94 Million USD | 755.751% |
| Precigen, Inc. | -95.9 Million USD | 393.621% |
| Pharming Group N.V. | -10.54 Million USD | 2769.644% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 239.685% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 1247.35% |
| PureTech Health plc | -65.69 Million USD | 528.625% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 1222.291% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 232.69% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 1256.952% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 209.217% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 1133.828% |
| Acelyrin, Inc. | -381.64 Million USD | 173.785% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 2245184.587% |
| Summit Therapeutics Inc. | -614.92 Million USD | 145.793% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 925.765% |
| Senti Biosciences, Inc. | -92.91 Million USD | 403.053% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 368.956% |
| Elevation Oncology, Inc. | -45.7 Million USD | 716.126% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 901.349% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 2254.199% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 4312.326% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 1059.042% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 3412.481% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 589.618% |
| Seer, Inc. | -86.27 Million USD | 426.384% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 520.321% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 528.182% |
| ESSA Pharma Inc. | -26.58 Million USD | 1159.327% |
| GlycoMimetics, Inc. | -36.89 Million USD | 863.139% |
| GT Biopharma, Inc. | -7.59 Million USD | 3806.647% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 216.669% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 642.309% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -294.334% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 617.427% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 673.278% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 2930.732% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 149.157% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 7948.216% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 651.518% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 214.658% |
| Aptose Biosciences Inc. | -51.2 Million USD | 649.913% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 386.47% |
| Soligenix, Inc. | -6.14 Million USD | 4685.676% |
| Century Therapeutics, Inc. | -136.67 Million USD | 306.035% |
| Kura Oncology, Inc. | -152.63 Million USD | 284.493% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 415.625% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 2772.177% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -49698.221% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 49589.279% |
| Autolus Therapeutics plc | -208.38 Million USD | 235.133% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 491.658% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 497.76% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 1399.585% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 225.014% |
| GRI Bio, Inc. | -13.03 Million USD | 2259.96% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 6910.707% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 326.938% |
| IGM Biosciences, Inc. | -246.41 Million USD | 214.276% |
| INmune Bio, Inc. | -30 Million USD | 1038.396% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 354.7% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 767.383% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 1864.19% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 1882.807% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 571.8% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 378.346% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 201.98% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 218.371% |
| Verastem, Inc. | -87.36 Million USD | 422.312% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 619.661% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 274.539% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 341.384% |
| Histogen Inc. | -10.62 Million USD | 2751.295% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 2071.014% |
| Surrozen, Inc. | -43.04 Million USD | 754.231% |
| Organovo Holdings, Inc. | -14.67 Million USD | 2019.392% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 5635.53% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 638.02% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 1214.65% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 1145.341% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 3469.524% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 286.381% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 675.55% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 1047.331% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 2803.033% |
| Apollomics, Inc. | -172.6 Million USD | 263.147% |
| Amarin Corporation plc | -59.11 Million USD | 576.374% |
| Mesoblast Limited | -87.95 Million USD | 420.153% |
| Turnstone Biologics Corp. | -55.2 Million USD | 610.134% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 291.61% |
| Synaptogenix, Inc. | -6.03 Million USD | 4763.307% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 1837.377% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 460.925% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 5976.99% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 3451.433% |
| Exelixis, Inc. | 207.76 Million USD | -35.535% |
| Better Therapeutics, Inc. | -39.76 Million USD | 808.234% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 295.622% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 153.269% |
| NLS Pharmaceutics AG | -12.17 Million USD | 2413.452% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 3712.639% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 1015.783% |
| Gritstone bio, Inc. | -138.49 Million USD | 303.332% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 536.817% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 7139.938% |
| Avid Bioservices, Inc. | -140.75 Million USD | 300.063% |
| Insmed Incorporated | -749.56 Million USD | 137.568% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 1953.872% |
| MediWound Ltd. | -6.71 Million USD | 4292.883% |
| OmniAb, Inc. | -50.61 Million USD | 656.301% |
| Alector, Inc. | -130.39 Million USD | 315.961% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 347.612% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 643.125% |
| Zai Lab Limited | -334.62 Million USD | 184.153% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 186.915% |
| Aura Biosciences, Inc. | -76.4 Million USD | 468.54% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 220.015% |
| Immunic, Inc. | -93.61 Million USD | 400.81% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 307.217% |
| Veracyte, Inc. | -74.4 Million USD | 478.466% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 3768.714% |
| FibroGen, Inc. | -284.23 Million USD | 199.072% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 1173.475% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 4121.686% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 1595.24% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 32.119% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 1348.477% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -471.521% |
| TG Therapeutics, Inc. | 12.67 Million USD | -2122.175% |
| Galecto, Inc. | -38.34 Million USD | 834.293% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 1592.6% |
| Fortrea Holdings Inc. | -3.4 Million USD | 8382.176% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 322.351% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 1717.334% |
| XBiotech Inc. | -24.55 Million USD | 1246.695% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 536.817% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 549.257% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 386.097% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 1414.202% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 610.199% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 146.419% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 512.562% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 494697.253% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 224.303% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 1364.595% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 228.166% |
| NexImmune, Inc. | -32.34 Million USD | 970.612% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 5426.588% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 2104.814% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 92.878% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 1262.603% |
| Scopus BioPharma Inc. | -11.6 Million USD | 2525.48% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 341.095% |
| Ainos, Inc. | -13.77 Million USD | 2144.9% |
| Pluri Inc. | -20.88 Million USD | 1448.114% |
| Prothena Corporation plc | -147.02 Million USD | 291.524% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 347.292% |
| Celularity Inc. | -196.29 Million USD | 243.454% |
| Rallybio Corporation | -74.56 Million USD | 477.654% |
| Cue Biopharma, Inc. | -50.73 Million USD | 655.051% |
| MeiraGTx Holdings plc | -84.02 Million USD | 435.123% |
| Omeros Corporation | -117.81 Million USD | 339.018% |
| Humacyte, Inc. | -110.77 Million USD | 354.201% |
| Immunocore Holdings plc | -55.28 Million USD | 609.331% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 1665.803% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 1328.006% |
| Blueprint Medicines Corporation | -506.98 Million USD | 155.543% |
| CalciMedica, Inc. | -34.35 Million USD | 919.612% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 516.098% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 299.14% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 269.851% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 199.414% |
| Pulmatrix, Inc. | -14.12 Million USD | 2094.151% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 900.097% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 440.756% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 158.52% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 368.515% |
| Cytokinetics, Incorporated | -526.24 Million USD | 153.51% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 880.796% |
| Nutriband Inc. | -5.48 Million USD | 5233.599% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 796.67% |
| Vor Biopharma Inc. | -117.86 Million USD | 338.916% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 93.525% |
| Evogene Ltd. | -23.87 Million USD | 1279.254% |
| ProKidney Corp. | -35.46 Million USD | 893.938% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 335.126% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 3689.293% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 143.78% |
| CorMedix Inc. | -46.33 Million USD | 707.68% |
| BioLineRx Ltd. | -60.61 Million USD | 564.569% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 376.767% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 785.711% |
| Atai Life Sciences N.V. | -40.22 Million USD | 800.065% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 449.155% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 472.868% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 196.373% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 1110.166% |
| MediciNova, Inc. | -8.57 Million USD | 3385.23% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 328.424% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 3461.58% |
| GeoVax Labs, Inc. | -25.96 Million USD | 1184.44% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 217.705% |
| Biomea Fusion, Inc. | -117.25 Million USD | 340.155% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 144.94% |
| Mereo BioPharma Group plc | -29.46 Million USD | 1055.657% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 283.854% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 234.502% |
| Absci Corporation | -110.56 Million USD | 354.684% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 1033.977% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 379.257% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 219.351% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -1899.389% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 245.932% |
| Allakos Inc. | -185.7 Million USD | 251.638% |
| Imunon, Inc. | -19.51 Million USD | 1542.964% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 389.304% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -165.304% |
| BioAtla, Inc. | -123.46 Million USD | 328.082% |
| NLS Pharmaceutics AG | -12.17 Million USD | 2413.452% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 1851.424% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 186.045% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 862.115% |
| XOMA Corporation | -40.83 Million USD | 789.657% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 376.425% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 337.606% |
| aTyr Pharma, Inc. | -50.38 Million USD | 658.84% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 421.165% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 285.553% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 218.449% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 901.828% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 3579.932% |
| Akari Therapeutics, Plc | -10 Million USD | 2913.689% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 418360.676% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 4325.03% |
| UroGen Pharma Ltd. | -102.24 Million USD | 375.414% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 363.682% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 3720.771% |
| Orgenesis Inc. | -55.36 Million USD | 608.65% |
| Entera Bio Ltd. | -8.88 Million USD | 3267.893% |
| GH Research PLC | -35.58 Million USD | 891.283% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 1451.219% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 463.873% |
| Xencor, Inc. | -126.08 Million USD | 323.333% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 7577.862% |
| Replimune Group, Inc. | -215.79 Million USD | 230.492% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 1424.118% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -11123.356% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 4325.03% |
| Portage Biotech Inc. | -75.33 Million USD | 473.769% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 3461.58% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 391.339% |
| OncoCyte Corporation | -27.78 Million USD | 1113.621% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 2198.752% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 2631.974% |
| Purple Biotech Ltd. | -19.88 Million USD | 1516.469% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 4111.882% |
| scPharmaceuticals Inc. | -54.81 Million USD | 613.764% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 1708.544% |
| HilleVax, Inc. | -123.56 Million USD | 327.89% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 2886.128% |
| Tharimmune, Inc. | -9.31 Million USD | 3121.689% |
| Genprex, Inc. | -30.86 Million USD | 1012.475% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 219.357% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 1035.715% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 15902.132% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 5417.092% |
| OKYO Pharma Limited | -16.82 Thousand USD | 1673718.433% |
| Savara Inc. | -54.69 Million USD | 614.816% |
| Curis, Inc. | -47.41 Million USD | 693.917% |
| Daré Bioscience, Inc. | -30.16 Million USD | 1033.624% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 1923.195% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 5156.455% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 1044.471% |
| BeiGene, Ltd. | -881.7 Million USD | 131.937% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 1422.41% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 164.531% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 456.651% |
| Erasca, Inc. | -125.04 Million USD | 325.2% |
| bluebird bio, Inc. | -211.91 Million USD | 232.882% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 5731.32% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -67.97% |
| DBV Technologies S.A. | -72.72 Million USD | 487.199% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 5731.32% |
| Moderna, Inc. | -4.71 Billion USD | 105.974% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 801.233% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 5045.451% |
| Molecular Templates, Inc. | -8.12 Million USD | 3566.199% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 566.308% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 352.78% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 308.046% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 687.646% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 299.106% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 246.351% |
| MacroGenics, Inc. | -9.05 Million USD | 3208.788% |
| RenovoRx, Inc. | -10.23 Million USD | 2852.091% |
| Adicet Bio, Inc. | -142.65 Million USD | 297.391% |
| Prime Medicine, Inc. | -198.13 Million USD | 242.124% |
| Aditxt, Inc. | -32.38 Million USD | 969.632% |
| Adagene Inc. | -18.94 Million USD | 1586.269% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 3951.267% |
| Quantum-Si incorporated | -95.96 Million USD | 393.449% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 336.576% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 2031.667% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -112.797% |
| SciSparc Ltd. | -5.12 Million USD | 5597.735% |
| Vericel Corporation | -3.18 Million USD | 8949.591% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 234266.015% |
| Minerva Neurosciences, Inc. | -30 Million USD | 1038.479% |
| Generation Bio Co. | -126.61 Million USD | 322.407% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 486.322% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 441.566% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 207.421% |
| Invivyd, Inc. | -198.64 Million USD | 241.759% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 182.344% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 3341.716% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -1134.736% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 2951.874% |
| 2seventy bio, Inc. | -217.57 Million USD | 229.427% |
| ADMA Biologics, Inc. | -28.23 Million USD | 1097.181% |
| Clene Inc. | -49.5 Million USD | 668.831% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 1363.459% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 669.636% |
| GeoVax Labs, Inc. | -25.96 Million USD | 1184.44% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 185.835% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 965.301% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -1139.41% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 385.038% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 476.694% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 275.115% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 145.783% |
| Evaxion Biotech A/S | -22.12 Million USD | 1372.741% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 448.784% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 240.749% |
| Trevena, Inc. | -40.28 Million USD | 798.935% |
| Surrozen, Inc. | -43.04 Million USD | 754.231% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 507.316% |
| Cingulate Inc. | -23.53 Million USD | 1296.493% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 4173.987% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 806.458% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 3752.003% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 412.154% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 559.475% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 573.243% |
| Clearmind Medicine Inc. | -11.95 Million USD | 2455.443% |
| Kronos Bio, Inc. | -112.67 Million USD | 349.921% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 506.945% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 11102957.391% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 427.835% |
| Statera Biopharma, Inc. | -174.4 Million USD | 261.457% |
| ImmunityBio, Inc. | -583.19 Million USD | 148.285% |
| Korro Bio, Inc. | -81.17 Million USD | 446.91% |
| Kineta, Inc. | -14.09 Million USD | 2097.262% |
| BioVie Inc. | -32.12 Million USD | 976.679% |
| Codexis, Inc. | -76.24 Million USD | 469.352% |
| Celularity Inc. | -196.29 Million USD | 243.454% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 231.262% |
| Celcuity Inc. | -63.77 Million USD | 541.514% |
| Virax Biolabs Group Limited | -6.73 Million USD | 4281.963% |
| Cibus, Inc. | -267.62 Million USD | 205.219% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 798.294% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 886.334% |
| IN8bio, Inc. | -30 Million USD | 1038.428% |
| Kodiak Sciences Inc. | -260.49 Million USD | 208.101% |
| Annexon, Inc. | -134.23 Million USD | 309.774% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 340.34% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 559.91% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 992.702% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 176.878% |
| Eyenovia, Inc. | -27.26 Million USD | 1132.952% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -1204.219% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 52734.393% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 468.559% |
| Arcellx, Inc. | -70.69 Million USD | 498.351% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 779.506% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 310.434% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 1037.49% |
| Moolec Science SA | -51.78 Million USD | 643.734% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 637.691% |
| Geron Corporation | -184.12 Million USD | 252.935% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 770.877% |
| Royalty Pharma plc | 1.13 Billion USD | 75.186% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 307.121% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 3266.894% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 1425.57% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 264.032% |
| Humacyte, Inc. | -110.77 Million USD | 354.201% |
| Structure Therapeutics Inc. | -89.62 Million USD | 414.209% |
| 89bio, Inc. | -142.18 Million USD | 298.042% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 508.344% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 2813.636% |
| Genelux Corporation | -28.29 Million USD | 1095.137% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 1068.842% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 258.986% |
| Notable Labs, Ltd. | -11.26 Million USD | 2599.947% |
| Liquidia Corporation | -78.5 Million USD | 458.709% |
| Mustang Bio, Inc. | -51.6 Million USD | 645.704% |
| Immunovant, Inc. | -259.33 Million USD | 208.583% |
| Quantum-Si incorporated | -95.96 Million USD | 393.449% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 486.545% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 1552.938% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 393.358% |
| Acasti Pharma Inc. | -12.85 Million USD | 2290.882% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 1353.877% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 1864.19% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 254.389% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 6646.388% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 2358.172% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 1054.847% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 822.258% |
| PepGen Inc. | -78.62 Million USD | 458.144% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 1045.93% |
| United Therapeutics Corporation | 984.8 Million USD | 71.406% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 1365.022% |
| Solid Biosciences Inc. | -96.01 Million USD | 393.281% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 5976.99% |
| Immuneering Corporation | -53.47 Million USD | 626.623% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 5635.53% |
| Silo Pharma, Inc. | -3.7 Million USD | 7709.244% |
| Belite Bio, Inc | -31.63 Million USD | 990.219% |
| XOMA Corporation | -40.83 Million USD | 789.657% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 617.969% |
| Bionomics Limited | -15.49 Billion USD | 101.818% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 435.291% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 1065.785% |
| uniQure N.V. | -308.47 Million USD | 191.285% |
| Cassava Sciences, Inc. | -97.21 Million USD | 389.655% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 3951.267% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 328.141% |
| Forte Biosciences, Inc. | -31.47 Million USD | 994.631% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 3533.36% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 1068.742% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 52734.393% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 1173.475% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 1808.183% |
| Altimmune, Inc. | -88.44 Million USD | 418.376% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 285.768% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 1065.785% |
| Compugen Ltd. | -18.75 Million USD | 1601.514% |
| Peak Bio, Inc. | -1259.26 USD | 22361963.317% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 711.509% |
| Benitec Biopharma Inc. | -21.75 Million USD | 1394.626% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 183.118% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 439.458% |
| Zura Bio Limited | -60.36 Million USD | 566.524% |
| PolyPid Ltd. | -23.86 Million USD | 1279.946% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 1889.944% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 439.458% |
| Instil Bio, Inc. | -156.08 Million USD | 280.408% |
| argenx SE | -295.05 Million USD | 195.438% |
| Immunome, Inc. | -106.8 Million USD | 363.65% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 762.668% |
| Verona Pharma plc | -54.36 Million USD | 617.931% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 381.828% |
| Shattuck Labs, Inc. | -87.29 Million USD | 422.566% |
| CervoMed Inc. | -2.17 Million USD | 13065.491% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 325.906% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 2214.704% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 746.525% |
| Moolec Science SA | -51.78 Million USD | 643.734% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 1628589.457% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 308.407% |
| AnaptysBio, Inc. | -163.61 Million USD | 272.103% |
| Design Therapeutics, Inc. | -66.86 Million USD | 521.157% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 445.879% |
| NeurAxis, Inc. | -14.62 Million USD | 2025.208% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 843.345% |
| Lumos Pharma, Inc. | -34.03 Million USD | 927.39% |
| Achilles Therapeutics plc | -69.66 Million USD | 504.212% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 381.828% |
| 180 Life Sciences Corp. | -19.93 Million USD | 1512.553% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -9259.045% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 11102957.391% |
| Nutriband Inc. | -5.48 Million USD | 5233.599% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 379.645% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 679.328% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 465.275% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 928.949% |
| MoonLake Immunotherapeutics | -36 Million USD | 882.048% |
| Palisade Bio, Inc. | -12.3 Million USD | 2389.382% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 768.488% |
| Beam Therapeutics Inc. | -132.52 Million USD | 312.48% |
| Neurogene Inc. | -36.31 Million USD | 875.378% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 272.318% |
| AEON Biopharma, Inc. | -52.55 Million USD | 635.798% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 386.91% |
| Sesen Bio, Inc. | -19.88 Million USD | 1516.184% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 493.376% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 2350.25% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 163.417% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 352.401% |
| Athira Pharma, Inc. | -117.67 Million USD | 339.304% |
| Vaccinex, Inc. | -20.25 Million USD | 1490.519% |
| HCW Biologics Inc. | -24.99 Million USD | 1226.634% |
| XOMA Corporation | -40.83 Million USD | 789.657% |
| Nektar Therapeutics | -276.05 Million USD | 202.006% |
| Arvinas, Inc. | -367.3 Million USD | 176.666% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 418360.676% |
| Merus N.V. | -154.93 Million USD | 281.745% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 389.028% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 997.225% |
| Rezolute, Inc. | -68.45 Million USD | 511.332% |
| Clene Inc. | -49.5 Million USD | 668.831% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 1925.75% |
| BeyondSpring Inc. | -21.02 Million USD | 1439.266% |
| Synlogic, Inc. | -57.28 Million USD | 591.592% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 2466.137% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 2701.09% |
| Peak Bio, Inc. | -1259.26 USD | 22361963.317% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 853.57% |
| Krystal Biotech, Inc. | 10.93 Million USD | -2475.869% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 296.783% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 186.617% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 6196.474% |
| MannKind Corporation | -11.93 Million USD | 2458.804% |
| Ikena Oncology, Inc. | -68.16 Million USD | 513.1% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 1439.967% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 403.008% |
| Gossamer Bio, Inc. | -179.81 Million USD | 256.6% |
| CohBar, Inc. | -11.96 Million USD | 2454.048% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 1191.957% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 1033.977% |
| Legend Biotech Corporation | -518.25 Million USD | 154.335% |
| Mural Oncology plc | -207.44 Million USD | 235.743% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 326.882% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 1639.629% |
| Disc Medicine, Inc. | -76.42 Million USD | 468.439% |
| Champions Oncology, Inc. | -7.27 Million USD | 3970.176% |
| REGENXBIO Inc. | -263.49 Million USD | 206.869% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 2753.275% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 692.767% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 841.359% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 381.136% |
| Vaxart, Inc. | -82.46 Million USD | 441.471% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -84269.448% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 850.067% |
| Cellectis S.A. | -101.05 Million USD | 378.643% |
| Longeveron Inc. | -21.41 Million USD | 1415.061% |
| Repare Therapeutics Inc. | -93.79 Million USD | 400.22% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 152.538% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 495.669% |
| Revolution Medicines, Inc. | -436.36 Million USD | 164.531% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 4385.406% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 1013.554% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 506.147% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 535.015% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 2970.187% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 92.22% |
| Denali Therapeutics Inc. | -145.22 Million USD | 293.903% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 234266.015% |
| Veru Inc. | -93.15 Million USD | 402.293% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 1141.822% |
| Cingulate Inc. | -23.53 Million USD | 1296.493% |
| Passage Bio, Inc. | -102.06 Million USD | 375.905% |
| Context Therapeutics Inc. | -23.96 Million USD | 1275.061% |
| Exicure, Inc. | -16.91 Million USD | 1764.858% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 249.057% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 845.668% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 4427.339% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 252.478% |
| Nuvalent, Inc. | -126.21 Million USD | 323.1% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 2777.855% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 424.122% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 1021.929% |
| OmniAb, Inc. | -50.61 Million USD | 656.301% |
| Anew Medical, Inc. | 1.34 Million USD | -20818.86% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 1855.026% |
| Lipocine Inc. | -16.35 Million USD | 1822.068% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 524.126% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 542.236% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 767.383% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 687.058% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 1519.969% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 152.004% |
| Ocugen, Inc. | -63.07 Million USD | 546.422% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 394.148% |
| Q32 Bio Inc. | -112.96 Million USD | 349.284% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 1737.936% |
| Alumis Inc. Common Stock | -154.99 Million USD | 281.682% |
| Equillium, Inc. | -13.33 Million USD | 2211.691% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 566.478% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 3625.285% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 1593.77% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 576.616% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 345.876% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 1632.238% |
| Dominari Holdings Inc. | -22.88 Million USD | 1330.635% |
| Edesa Biotech, Inc. | -8.37 Million USD | 3462.551% |
| vTv Therapeutics Inc. | -20.25 Million USD | 1490.588% |
| Bio-Techne Corporation | 168.1 Million USD | -67.511% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 179.978% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -118.539% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 331.133% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 842.228% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 349.99% |
| Nkarta, Inc. | -117.5 Million USD | 339.652% |
| BioCardia, Inc. | -11.57 Million USD | 2533.619% |
| Iterum Therapeutics plc | -38.37 Million USD | 833.872% |